Patents by Inventor Fabrizio Micheli

Fabrizio Micheli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Small-molecule PI5P4K alpha/beta inhibitors and methods of treatment using same
    Patent number: 11773096
    Abstract: The present-disclosure relates to the discovery of novel 2-amino-dihydropteridinone compounds and analogues thereof, which are capable of inhibiting phosphatidylinositol phosphate kinases. In certain embodiments, the compounds of the present disclosure can be used to treat p53-null cancer in a subject. In other embodiments, the compounds of the present disclosure can be used to treat metabolic disorders in a subject, including but not limited to type 2 diabetes and/or obesity.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: October 3, 2023
    Assignee: YALE UNIVERSITY
    Inventors: Ya Ha, Jonathan Ellman, Song Chen, Caroline Chandra Tjin, Fabrizio Micheli, Agostino Cianciulli, Claudia Beato
  • ANTAGONISTS OF GPR39 PROTEIN
    Publication number: 20230174484
    Abstract: Novel compounds that act as antagonists to human GPR39 protein are disclosed. Pharmaceutical compositions and methods of use for antagonists to human GPR39 protein are disclosed. In particular, methods of using the antagonists in the treatment of diseases or conditions including cardiovascular conditions, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases are disclosed herein.
    Type: Application
    Filed: April 30, 2021
    Publication date: June 8, 2023
    Inventors: Sanjiv KAUL, Nabil ALKAYED, Shanthi NAGARAJAN, Agostino CIANCIULLI, Fabrizio MICHELI, Teresa SEMERARO, Iuni Margaret Laura TRIST
  • Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
    Patent number: 11660293
    Abstract: There is provided a compound of formula (I), wherein L1 to L3?, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: May 30, 2023
    Assignee: CHRONOS THERAPEUTICS LIMITED
    Inventors: Fabrizio Micheli, Barbara Bertani, Karl Richard Gibson, Romano Di Fabio, Luca Raveglia, Riccardo Zanaletti, Susanna Cremonesi, Alfonso Pozzan, Teresa Semeraro, Luca Tarsi, Timothy Jon Luker
  • Complement Modulators and Related Methods
    Publication number: 20230115176
    Abstract: The present disclosure presents compounds and compositions that interact with complement components. Some compounds inhibit complement activity. Included are small molecule compounds and compositions that function as C5 inhibitor compounds. Methods for inhibiting complement activity and methods of treating complement-related indications with the C5 inhibitor compounds and compositions are provided.
    Type: Application
    Filed: March 27, 2020
    Publication date: April 13, 2023
    Inventors: Willmen Wing-Menn Youngsaye, Bolin Geng, Michael R. Hale, Vincent P. Galullo, Jayashree G. Tikhe, Timothy Ryan Siegert, Alonso Ricardo, Derek M. LaPlaca, Douangsone D. Vadysirisack, Guo-Qing Tang, Kathleen Seyb, Michelle Denise Hoarty, Jonathan C. Blain, Joseph R. Stringer, Yongjin Gong, Claudio Sturino, Shawn Gallagher-Duval, Colin Diner, Burcin Akgun, Qing Cao, Douglas A. Treco, Vaishnavi Rajagopal, Ketki Ashok Dhamnaskar, Zhong Ma, Susan Ashwell, Jennifer Davoren, Xiaorong Liu, Camil Sayegh, Wenqing Xu, Alex Lemire, Audrey Belouin, Alexandria Jeanneret, Andrew Hildering, Barbara Bertani, Fabrizio MIcheli, Bemardo Pezzati, Alfonso Pozzan
  • SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20220331299
    Abstract: There is provided a compound of formula (I), wherein L1 to L3?, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.
    Type: Application
    Filed: August 31, 2018
    Publication date: October 20, 2022
    Inventors: Fabrizio Micheli, Barbara Bertani, Karl Richard Gibson, Romano Di Fabio, Luca Raveglia, Riccardo Zanaletti, Susanna Cremonesi, Alfonso Pozzan, Teresa Semeraro, Luca Tarsi, Timothy Jon Luker
  • Small-Molecule PI5P4K alpha/beta Inhibitors and Methods of Treatment Using Same
    Publication number: 20210292326
    Abstract: The present-disclosure relates to the discovery of novel 2-amino-dihydropteridinone compounds and analogues thereof, which are capable of inhibiting phosphatidylinositol phosphate kinases. In certain embodiments, the compounds of the present disclosure can be used to treat p53-null cancer in a subject. In other embodiments, the compounds of the present disclosure can be used to treat metabolic disorders in a subject, including but not limited to type 2 diabetes and/or obesity.
    Type: Application
    Filed: August 9, 2019
    Publication date: September 23, 2021
    Inventors: Ya Ha, Jonathan Ellman, Song Chen, Caroline Chandra Tjin, Fabrizio Micheli, Agostino Cianciulli, Claudia Beato
  • Dopamine Dreceptor antagonist compounds
    Patent number: 10654842
    Abstract: The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: May 19, 2020
    Assignee: INDIVIOR UK LIMITED
    Inventors: Susanna Cremonesi, Fabrizio Micheli, Teresa Semeraro, Luca Tarsi
  • Substituted 3,6-diazabicyclo[3.2.0]heptanes
    Patent number: 10584135
    Abstract: The disclosure provides compounds having formula (I), where the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: March 10, 2020
    Assignee: INDIVIOR UK LIMITED
    Inventors: Susanna Cremonesi, Fabrizio Micheli, Teresa Semeraro, Luca Tarsi
  • Dopamine D3 receptor antagonists having a morpholine moiety
    Patent number: 10577361
    Abstract: The disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof: The disclosure also provides processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them, and their use as modulators of dopamine D3 receptors, such as treating substance abuse or psychiatric diseases.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: March 3, 2020
    Assignee: INDIVIOR UK LIMITED
    Inventors: Susana Cremonesi, Fabrizio Micheli, Teresa Semeraro, Luca Tarsi
  • DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS
    Publication number: 20190300514
    Abstract: The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.
    Type: Application
    Filed: January 29, 2019
    Publication date: October 3, 2019
    Inventors: Susanna Cremonesi, Fabrizio Micheli, Teresa Semeraro, Luca Tarsi
  • DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY
    Publication number: 20190194225
    Abstract: The disclosure provides compounds having formula (I), where the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.
    Type: Application
    Filed: March 4, 2019
    Publication date: June 27, 2019
    Inventors: Susanna Cremonesi, Fabrizio Micheli, Teresa Semeraro, Luca Tarsi
  • Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulators
    Patent number: 10273244
    Abstract: The disclosure provides compounds having formula (I), wherein the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: April 30, 2019
    Assignee: INDIVIOR UK LIMITED
    Inventors: Fabrizio Micheli, Susanna Cremonesi, Teresa Semeraro, Luca Tarsi
  • Dopamine D3 receptor antagonists
    Patent number: 10239870
    Abstract: The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: March 26, 2019
    Assignee: Indivior UK Limited
    Inventors: Susanna Cremonesi, Fabrizio Micheli, Teresa Semerano, Luca Tarsi
  • DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY
    Publication number: 20180297990
    Abstract: The disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof: The disclosure also provides processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them, and their use as modulators of dopamine D3 receptors, such as treating substance abuse or psychiatric diseases.
    Type: Application
    Filed: October 13, 2016
    Publication date: October 18, 2018
    Inventors: Susana Cremonesi, Fabrizio Micheli, Teresa Semeraro, Luca Tarsi
  • DOPAMINE D3 RECEPTOR ANTAGONISTS
    Publication number: 20180282318
    Abstract: The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.
    Type: Application
    Filed: May 9, 2018
    Publication date: October 4, 2018
    Inventors: Susanna Cremonesi, Fabrizio Micheli, Teresa Semerano, Luca Tarsi
  • DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY
    Publication number: 20180222918
    Abstract: The disclosure provides compounds having formula (I), wherein the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.
    Type: Application
    Filed: August 4, 2016
    Publication date: August 9, 2018
    Inventors: Susanna Cremonesi, Fabrizio Micheli, Teresa Semeraro, Luca Tarsi
  • Dopamine D3 receptor antagonist compounds
    Patent number: 10000477
    Abstract: The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: June 19, 2018
    Assignee: Indivior UK Limited
    Inventors: Susanna Cremonesi, Fabrizio Micheli, Teresa Semeraro, Luca Tarsi
  • N-(hetero)aryl-substituted heteroyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system
    Patent number: 9920053
    Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R9a, R9b, R9c, R9d, R9e, R9f, m, n, A, L and B are as defined herein.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: March 20, 2018
    Assignee: CHRONOS THERAPEUTICS LIMITED
    Inventors: Susanna Cremonesi, Fabrizio Micheli, Teresa Semeraro, Luca Tarsi, Tim Luker, Colin Leslie
  • Spirocyclic derivatives
    Patent number: 9908897
    Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R5, R6, R9, R10, Q, X, Y, Z, A, L, B, m, n and p are as defined herein.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: March 6, 2018
    Assignee: CHRONOS THERAPEUTICS LIMITED
    Inventors: Susanna Cremonesi, Tim Luker, Teresa Semeraro, Fabrizio Micheli
  • DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS
    Publication number: 20170334895
    Abstract: The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.
    Type: Application
    Filed: October 30, 2015
    Publication date: November 23, 2017
    Inventors: Susanna Cremonesi, Fabrizio Micheli, Teresa Semeraro, Luca Tarsi